(LPTH) Supplies Infrared Molded Optics for Firefighting Thermal Imaging Cameras

(NAVB) Reports Positive Lymphoseek® Breast Cancer Comparative Results

Navidea Biopharmaceuticals (NYSE MKT: NAVB), announced that results from an investigator-initiated, comparative study of Lymphoseek® (technetium Tc 99m tilmanocept) injection versus filtered Tc-99m Sulfur Colloid (fTcSC) measuring injection site pain in patients with breast cancer undergoing lymphoscintigraphy were presented at the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. The results of the randomized, double-blinded trial, led by Anne Wallace, M.D., professor of surgery at University of California, San Diego School of Medicine, highlighted that fTcSC caused statistically significant greater levels of pain after injection compared to Lymphoseek.

In preparation for Sentinel Lymph Node Biopsy in breast cancer and other cancers, lymphatic pathways are mapped using a procedure called lymphoscintigraphy. “Patients often fear this procedure given the evidence of injection pain from some radiotracers,” said Dr. Wallace, who is also director of the Comprehensive Breast Health Center at UC San Diego Moores Cancer Center. “This study of tilmanocept demonstrated, with patient-reported data, a significantly reduced level of post-injection associated pain compared with use of an fTcSC tracer. Along with its other desirable performance characteristics, surgeons now have a reliable tool that can potentially play an important role in improved patient comfort and management.”

“This investigator-initiated study is of particular importance as it continues to reinforce the clinical value of Lymphoseek,” said Michael Tomblyn, M.D., Navidea’s Executive Medical Director. “While previous studies have reported on Lymphoseek efficacy and ongoing safety, these results further illustrate both the clinical utility and clear benefits to both surgical oncologists and patients.”

The poster presentation entitled, ”A Randomized Double-Blinded Comparison of Injection Site Pain of Tc-99m Tilmanocept versus Filtered Tc-99m Sulfur Colloid in Patients Undergoing Lymph Node Mapping for Breast Cancer” showed results of the randomized, double-blind clinical trial comparing post-injection site pain using fTcSC versus Lymphoseek in 52 [(27) fTcSC and (25) Lymphoseek] breast cancer patients undergoing lymphoscintigraphy. Pain was evaluated with a visual analogue scale and short form McGill Pain Questionnaire at 1, 2, 3, 4, 5, 15 and 30 minutes post-injection. Analysis of the data indicates baseline pain scores were similar between groups. At one minute post-injection, patients receiving fTcSC experienced a mean change in pain of 16.8mm (standard deviation (SD) 19.5) compared to 0.2mm (SD 7.3) in the Lymphoseek group (p =0.0002). Overall, patients receiving Lymphoseek experienced statistically significant less change in pain scores compared to patients receiving fTcSC at 1-3 minutes post-injection.

About Lymphoseek

Lymphoseek^® (technetium Tc 99m tilmanocept) injection is the first and only FDA-approved receptor-targeted lymphatic mapping agent. It is a novel, receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. Lymphoseek is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Lymphoseek is approved by the U.S. Food and Drug Administration (FDA) for use in solid tumor cancers where lymphatic mapping is a component of surgical management and for guiding sentinel lymph node biopsy in patients with clinically node negative breast cancer, melanoma or squamous cell carcinoma of the oral cavity. Lymphoseek has also received European approval in imaging and intraoperative detection of sentinel lymph nodes in patients with melanoma, breast cancer or localized squamous cell carcinoma of the oral cavity.

Accurate diagnostic evaluation of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. Overall in the U.S., solid tumor cancers may represent up to 1.2 million cases per year. The sentinel node label in the U.S. and Europe may address approximately 235,000 new cases of breast cancer, 76,000 new cases of melanoma and 45,000 new cases of head and neck/oral cancer in the U.S., and approximately 367,000 new cases of breast cancer, 83,000 new cases of melanoma and 55,000 new cases of head and neck/oral cancer diagnosed in Europe annually.

Lymphoseek Indication and Important Safety Information

Lymphoseek is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

• Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.
• Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Important Safety Information

In clinical trials with Lymphoseek, no serious hypersensitivity reactions were reported, however Lymphoseek may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of Lymphoseek, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of Lymphoseek administration, and patients observed for signs or symptoms of hypersensitivity following injection.

Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.

In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (<1%).

FULL LYMPHOSEEK PRESCRIBING INFORMATION CAN BE FOUND AT:
WWW.LYMPHOSEEK.COM

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek^® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150608006395/en/

(SYMX) Commissioning Phase at 1st of 3 (ACH) Syngas Gasification Plants

$23 Million Technology and Equipment Supply for Three New Clean Coal Natural Gas Replacement Projects Featuring SES Gasification Technology is First Order Secured by SES’ China JV, Tianwo-SES Clean Energy Technologies Company

HOUSTON, June 8, 2015  — Synthesis Energy Systems, Inc. (SES) (Nasdaq:SYMX), a global energy and gasification technology company enabling clean, high-value energy and chemical products from multiple feedstocks, announced that the first of three previously announced industrial syngas gasification plants from its Tianwo-SES Joint Venture has entered the commissioning phase. The plant, in Zibo City, Shandong Province, China, is owned and operated by Aluminum Corporation of China Limited (NYSE:ACH) (HKEx:2600) (SSE:601600), and utilizes two SES Gasification Technology systems supplied by Tianwo-SES. These gasification systems are uniquely suited to generate clean and economical syngas from local, low-grade lignite coal which will replace the purchase of more expensive natural gas. The Shandong facility is projected to enter commercial operation this year. The two additional Aluminum Corporation of China plants, in Shanxi and Henan Provinces, are currently under construction in a phased, fast-track timeline. Once all three projects enter commercial operation, the installed base for SES Gasification Technology will expand from five to 12 gasification systems in operation in China.

Total construction order commitments of $105 million (650 million Yuan) for the three projects were announced in December 2014 between Aluminum Corporation of China, China’s largest alumina and primary aluminum producer, and Innovative Coal Chemical Design Institute (Shanghai) Co., Ltd. (ICCDI). ICCDI is the general contractor supplying all the engineering, construction and balance of plant equipment for the three projects. The total order value for these projects to Tianwo-SES for technology and equipment supply from ICCDI, a subsidiary of Suzhou Thvow Technology Co., Ltd. (STT) (Shenzhen listing code:002564), is expected to be $23 million. Tianwo-SES Clean Energy Technologies Co., Ltd. (Tianwo-SES) is SES’s joint venture with STT.

“Late last year, China Shandong Aluminum Industry Branch, Henan Branch and Shanxi Aluminum Co., Ltd. contracted ICCDI to build these three important projects. Through great cooperation of all the parties, the Shandong Aluminum Project is now the first to begin commissioning and is driving for fast completion. Securing these three major China Aluminum projects is taking Suzhou Thvow Technology from a high-end equipment manufacturer to now include technology, research and development, and engineering services, to provide one total high-tech package solution for clean energy. With our partner SES, our Tianwo-SES company is driving to become a world leader in clean energy technology,” stated STT Chairman Chen Yu Zhong.

“The ICCDI and Tianwo-SES teams are to be commended for accomplishing this very fast project execution schedule and achieving this six-month commissioning milestone. These first orders are expected to deliver the first significant revenues to Tianwo-SES, and the speed and ease of construction demonstrates the turnkey simplicity of deploying the advanced SES Gasification Technology,” said DeLome Fair, President of SES Technologies, LLC. “These plants are expected to be the model for future projects in the growing natural gas replacement market in China. Based on our analysis, we believe the estimated cost savings to Aluminum Corporation of China at the Shandong plant alone will be in the order of $50,000 per day.

“We are making good traction in China and congratulate our China JV partner, Suzhou Thvow Technology, on securing the award for these groundbreaking projects. We believe replacement gas, which enables Growth With Blue Skies, represents a significant market segment for new plants and the retrofit of large numbers of existing facilities in the region, supplying clean and economical fuel gas to numerous industries. Tianwo-SES reports seven similar projects in its growing pipeline,” added Ms. Fair.

About Synthesis Energy Systems, Inc.

Synthesis Energy Systems (SES) is a Houston-based technology company focused on bringing clean high-value energy to developing countries from low-cost and low-grade coal and biomass through its proprietary gasification technology based upon U-Gas®, licensed from the Gas Technology Institute. The SES Gasification Technology enables Growth With Blue Skies, and greater fuel flexibility for both large-scale and efficient small- to medium-scale operations close to fuel sources. Fuel sources include low-rank, low-cost high ash, high moisture coals, which are significantly cheaper than higher grade coals, many coal waste products, and biomass feedstocks. For more information, please visit: www.synthesisenergy.com.

About Tianwo-SES Clean Energy Technologies Co., Ltd. 

Tianwo-SES Clean Energy Technologies Co., Ltd. (Tianwo-SES) is a joint venture between Synthesis Energy System’s wholly owned subsidiary, SES Asia Technologies, Ltd. and Suzhou Thvow Technology Co., Ltd. (STT). The joint venture was formed in 2014 to bring clean energy technologies and turnkey SES gasification systems to China and select Asian markets, combining SES’s advanced proprietary gasification technology with the market reach of one of China’s leading coal-chemical equipment manufacturers. The joint venture’s target markets also include Indonesia, Malaysia, Mongolia, the Philippines, and Vietnam. SES owns 35%, and STT owns 65%, of Tianwo-SES. For more information on STT, visit: http://www.thvow.com/main_en.

About Innovative Coal Chemical Design Institute (Shanghai) Co., Ltd.       

Innovative Coal Chemical Design Institute (Shanghai) Co., Ltd. (ICCDI) is based on the restructuring of Coking Design Institute of Shanghai Pacific Chemical Company affiliated Shanghai Huayi Group which is the largest and oldest chemical group under Shanghai municipal government. On October 15, 2010, ICCDI was transformed from a state-owned company into private one, and is 95% owned by Suzhou Thvow Tianwo Technology Co., Ltd. (Thvow). ICCDI is a Class-A design institute with class-A license in chemicals design, class-A license in engineering consulting and class-A license in Evaluation on energy saving. For more information on ICCDI, visit: http://www.iccdi.com.cn/en/.

About Aluminum Corporation of China Limited

Aluminum Corporation of China Limited (CHALCO) is China’s largest alumina and primary aluminum producer and the world’s second largest alumina producer. CHALCO was established as a joint stock limited company in the People’s Republic of China on September 10, 2001 by way of promotion by Aluminum Corporation of China (CHINALCO), Guangxi Investment (Group) Co., Ltd. and Guizhou Provincial Materials Development and Investment Corporation. With a registered capital of RMB 11.049 billion, CHALCO owns ten branches, one research institute, and 12 subsidiaries. It was listed on the New York Stock Exchange, Inc. and the Hong Kong Stock Exchange on December 11 and 12, 2001, respectively (NYSE: ACH; Hong Kong listing code: 2600; Shanghai Stock Exchange listing code: 601600). For more information on CHALCO, visit: http://www.chalco.com.cn/zlgfen/index.htm

SES Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the ability of our ZZ joint venture to effectively operate XE’s methanol plant and produce methanol; the ability of our project with Yima to produce earnings and pay dividends; our ability to develop and expand business of the Tianwo-SES joint venture in the joint venture territory; our ability to successfully partner our technology business; our ability to develop our power business unit and marketing arrangement with GE and our other business verticals, including DRI steel, through our marketing arrangement with Midrex Technologies, and renewables; our ability to successfully develop the SES licensing business; events or circumstances which result in an impairment of assets, including, but not limited to, at our ZZ Joint Venture; our ability to reduce operating costs; our ability to make distributions and repatriate earnings from our Chinese operations; our limited history, and viability of our technology; commodity prices, including in particular methanol, and the availability and terms of financing; our ability to obtain the necessary approvals and permits for future projects; our ability to raise additional capital, if any, and our ability to estimate the sufficiency of existing capital resources; the sufficiency of internal controls and procedures; and our results of operations in countries outside of the U.S., where we are continuing to pursue and develop projects. Although SES believes that in making such forward-looking statements our expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected by us. SES cannot assure you that the assumptions upon which these statements are based will prove to have been correct.

Contact:

MDC Group
Investor Relations:
David Castaneda
Arsen Mugurdumov
414.351.9758
IR@synthesisenergy.com

Media Relations:
Susan Roush
747.222.7012
PR@synthesisenergy.com

(SEED) CEO Will Present in an Investor Meeting at Wells Fargo Securities

BEIJING, June 8, 2015  — Origin Agritech Limited (NASDAQ GS: SEED) (“Origin”, or the “Company”), a technology-focused supplier of crop seeds in China, today announced that Dr. Gengchen Han, Chairman and CEO of Origin, will present in an investor’s meeting organized by Wells Fargo Securities on June 16^th, 2015. In his presentation, Dr. Han is expected to discuss the strategic direction of new Origin Agritech and company’s capabilities in biotech corn seed development, corn seed breeding technologies, and seed production & distribution. His presentation materials will be filed with SEC before the meeting.

This investor’s meeting will be hosted by Wells Fargo Securities in Midtown Manhattan, New York City and will start at noon on June 16th, 2015. For interested investors, please contact Noelle Ulrich of Wells Fargo at Noelle.L.Ulrich@wellsfargo.com or Investor Relation of Origin Agritech at IR@originseed.com.cn.

About Origin

Founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, Origin Agritech Limited (NASDAQ GS: SEED) is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies in China, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please log on to the Company’s website at: www.originseed.com.cn.

Forward Looking Statement

This release contains forward-looking statements. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results to differ materially from those implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “targets,” “goals,” “projects,” “continue,” or variations of such words, similar expressions, or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Neither we nor any other person can assume responsibility for the accuracy and completeness of forward-looking statements. Important factors that may cause actual results to differ from expectations include, but are not limited to, those risk factors discussed in Origin’s filings with the SEC including its annual report on Form 20-F. We undertake no obligation to revise or update publicly any forward-looking statements for any reasons.

CONTACT:
Origin Agritech Limited
James Chen
Chief Financial Officer
james.chen@originseed.com.cn

Origin Agritech Investor Relations
IR@originseed.com.cn
+86-10-5890-7536

(BLDP) Inks $10 Million Deal to Power 33 Clean Energy Buses in China

VANCOUVER and BEIJING, June 8, 2015  – Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) today announced that it has signed definitive license and supply agreements with each of Nantong Zehe New Energy Technology Co., Ltd. (“Zehe”) and Guangdong Synergy Hydrogen Power Technology Co., Ltd. (“Synergy”) to provide fuel cell Power Products and Technology Solutions to support the planned deployment of an initial 33 fuel cell-powered buses in two Chinese cities. The deal has an estimated value of $10 million, the majority of which is expected to be recognized in 2015.

Ballard and Zehe are collaborating with electric bus manufacturer Jiangsu GreenWheel New Energy Electric Vehicle Co. Ltd. (www.greenwheelev.com) in the city of Rugao in Jiangsu province. Ballard and Synergy are collaborating with electric bus manufacturer Foshan Feichi Automobile Manufacturing Co. Ltd. (www.fsfeichi.com.cn) in the city of Yunfu in Guangdong province. The municipal governments in the cities of Yunfu and Rugao plan to have fuel cell bus fleets operating in revenue service in 2016.

The agreement was signed at a ceremony held today in Beijing and attended by dignitaries that included Mr. Guy Saint-Jacques, Canada’s Ambassador to China. At the ceremony, Randy MacEwen, Ballard President and CEO said, “We continue to see strong growth opportunities in China’s mass transit market where fuel cells are increasingly being discussed as the next generation of clean propulsion. This demand is being driven by China’s growing need for clean urban mass transit and air quality policies.”

In April 2015 Ballard announced an initial order from Zehe for the supply of FCvelocity^®-HD7 modules to power 8 buses, which now forms part of the new deal with Zehe. All of these modules are expected to be shipped by Ballard this year. At today’s ceremony, Ballard expanded its relationship with Zehe to include the supply of additional Power Products and Technology Solutions, including a non-exclusive license for local assembly of FCvelocity^®-HD7 power modules for use in clean energy buses in China. In addition, Ballard will be the exclusive supplier of its proprietary fuel cell stacks for use in power modules assembled under this deal. A similar deal was signed with Synergy.

Mr. Ma Jin Hua, Member of Rugao Municipal Standing Committee of C.P.C and Vice Secretary of Party Committee of RETDZ said, “It is important that we deal with experienced, market-leading companies in order to ensure successful delivery with the most advanced technology. This is one reason that Ballard Power Systems is the right choice for a program of such importance.”

Mr. Xu Guo, Member of Foshan / Yunfu Municipal Standing Committee of C.P.C and Vice Mayor of Foshan / Yunfu City added, “We are very pleased to be moving forward with this key initiative, in support of our government’s new energy program. Zero-emission fuel cell modules will form a critical element in our future bus deployments, contributing to a cleaner environment for Chinese citizens.”

The size and rapid growth of China’s economy has resulted in considerably larger carbon dioxide emissions than other nations. In 2013, for example, China’s carbon dioxide emissions from fossil fuels accounted for 29% of the global total, compared to 15% from the United States. As a result of air quality issues, a new energy program was launched in 2011, involving 48 Chinese cities with an objective of expanding public transit while also reducing the number of vehicles in cities. One of the program’s specific goals is to deploy more than 1,000 clean energy buses in each of the participating cities, taking advantage of Government subsidies to facilitate this expansion.

In support of China’s new energy program, fuel cell buses and electric buses are eligible for a subsidy of approximately USD$150,000, through 2017. In addition, hydrogen fueling stations are eligible for a further subsidy of approximately USD$650,000.

About Ballard Power Systems
Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) provides clean energy products that reduce customer costs and risks, and helps customers solve difficult technical and business challenges in their fuel cell programs. To learn more about Ballard, please visit www.ballard.com.

This release contains forward-looking statements concerning market demand for our products. These forward-looking statements reflect Ballard’s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any such forward-looking statements are based on Ballard’s assumptions relating to its financial forecasts and expectations regarding its product development efforts, manufacturing capacity, and market demand.

These statements involve risks and uncertainties that may cause Ballard’s actual results to be materially different, including general economic and regulatory changes, detrimental reliance on third parties, successfully achieving our business plans and achieving and sustaining profitability. For a detailed discussion of these and other risk factors that could affect Ballard’s future performance, please refer to Ballard’s most recent Annual Information Form. Readers should not place undue reliance on Ballard’s forward-looking statements and Ballard assumes no obligation to update or release any revisions to these forward looking statements, other than as required under applicable legislation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.  The Ballard Common Shares have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

(POZN) Strategic Acquisition of Tribute and Growth Capital Commitment

Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US$350 Million Capital Commitment from Deerfield-Led Syndicate to Fund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management Team with Record of Growth and Innovation

POZEN Inc.
Bill Hodges, Chief Financial Officer
919-913-1030

Stephanie Bonestell
Manager, Investor Relations & Public Relations
919-913-1030

James Golden or Joe Snodgrass
Joele Frank, Wilkinson, Brimmer & Katcher
212-355-4449

Tribute Pharmaceuticals Canada Inc.
Scott Langille, Chief Financial Officer
905-876-3166

(TBRA) Completes Patient Recruitment for CENTAUR Phase 2b Study

SOUTH SAN FRANCISCO, June 8, 2015  — Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it has completed recruitment for the Phase 2b CENTAUR study. CENTAUR is a global, double blind, placebo controlled, Phase 2b clinical trial evaluating the treatment effects of cenicriviroc (CVC) versus placebo in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis at high risk of progressive disease. NASH is a severe form of non-alcoholic fatty liver disease. Patients with NASH and risk factors such as liver fibrosis and type 2 diabetes or metabolic syndrome are often at higher risk for progression to more advanced liver complications such as cirrhosis and liver cancer. Results of the one-year primary endpoint are anticipated to be announced in mid-2016.

“To our knowledge, CENTAUR is the first NASH study to prospectively focus on high risk patients who are in most urgent need of therapy and is designed to assess multiple aspects of the disease over an extended, two-year period,” said Laurent Fischer, M.D., chief executive officer of Tobira. “The robust CENTAUR study also helps advance the understanding of NASH and potential surrogate endpoints by evaluating non-invasive measurements, biomarkers, and other exploratory endpoints.”

Tobira plans to submit further detail regarding study demographics for presentation at an upcoming scientific conference.

The primary endpoint of the CENTAUR study is a two-point improvement in NAS (NAFLD Activity Score) without progression of fibrosis. The study will evaluate additional surrogate endpoints, including resolution of NASH with no concurrent worsening of fibrosis stage and measures of fibrosis improvement. These endpoints have been the focus of subgroup analyses in other NASH studies as well as industry and regulatory agency dialog and Tobira anticipates they may form the basis for future regulatory approvals of therapies for NASH with liver fibrosis.

About Cenicriviroc (CVC) and Non-alcoholic Steatohepatitis (NASH)
CVC is an oral, once-daily, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways in NASH that cause liver damage and often lead to cirrhosis, liver cancer or liver failure. This mechanism differs from metabolic targets related to the pathogenesis of disease. Tobira believes this novel approach will establish CVC as both a single-agent and as a cornerstone treatment in multi-therapy regimens for NASH, for which there is currently no approved drug.

To date, over 600 subjects have been dosed with CVC in Phase 1 and Phase 2b clinical studies, including 115 HIV-1 infected subjects on treatment for up to 48 weeks. CVC has been granted Fast Track status in patients with NASH and liver fibrosis, the patient population at highest risk of progression to cirrhosis. For additional information on the CENTAUR study, please visit clinicaltrials.gov using the identifier NCT02217475 or www.centaurstudy.com.

NASH is an emerging health crisis impacting 3% to 5% of the U.S. population and 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. Additionally, this population is estimated to be three to five times larger than the size of the population with hepatitis C in the U.S.

About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV. Learn more about Tobira at www.tobiratherapeutics.com.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company’s clinical development of cenicriviroc (CVC), the potential timing and outcomes of clinical studies of CVC undertaken now or in the future; the ability of the company to timely source adequate supply of its development products from third party manufacturers on whom the company depends; the company’s limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all; the company’s ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company’s ability to protect the company’s intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company’s products; and other factors listed under “Risk Factors” in the company’s other filings with the Securities and Exchange Commission.

Tobira Contacts:
Chris Peetz
Chief Financial Officer
Tobira Therapeutics
(650) 351-5018
cpeetz@tobiratherapeutics.com

Mark Corbae
Canale Communications
(619) 849-5375
mark@canalecomm.com

(CRBP) Expands Clinical Development of Resunab(TM) With a Phase 2 Trial

Study at University of Pennsylvania School of Medicine Funded by the National Institutes of Health

(QUNR) Announces Pricing of its Offering of 6,526,316 American Depositary Shares

BEIJING, June 5, 2015  — Qunar Cayman Islands Limited (Nasdaq:QUNR) (“Qunar” or the “Company”), China’s leading mobile and online travel platform, today announced the pricing of its public offering of 6,526,316 American Depositary Shares (the “ADSs”) at a price of US$47.50 per ADS. Each ADS represents three Class B ordinary shares of the Company. The Company has granted to the underwriters a 30-day option to purchase up to an additional 315,790 ADSs.

The Company intends to use a majority of the net proceeds for general corporate purposes, including the acquisition of new users. The Company also may use a portion of the net proceeds to acquire complementary businesses, products, services or technologies. However, the Company has not yet entered into any agreements or commitments for any specific acquisitions at this time.

Goldman Sachs (Asia) L.L.C. is acting as sole bookrunner for the offering and BofA Merrill Lynch, Pacific Crest Securities and Stifel are acting as co-managers.

The ADSs will be issued pursuant to an effective shelf registration statement on Form F-3 previously filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov. A preliminary prospectus supplement and accompanying prospectus related to the ADS offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. When available, the final prospectus supplement for the offering of the ADSs will be filed with the SEC.

The offering of ADSs may be made only by means of a related prospectus supplement and accompanying prospectus. Before you invest, you should read the applicable prospectus supplement and accompanying base prospectus and other documents that the Company has filed with the SEC for more complete information about the Company and the offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov. Copies of the prospectus supplements and the accompanying prospectus related to the ADS offering may also be obtained from Goldman, Sachs & Co., 200 West Street, New York, NY 10282, Attention: Prospectus Department (telephone: 212-902-1171; e-mail: prospectus-ny@ny.email.gs.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase, nor shall there be any sale of, any of the securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The ADSs have not been and will not be registered under the applicable securities laws of any jurisdiction outside of the United States of America.

Forward-looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, Qunar’s strategic and operational plans, contain forward-looking statements. Qunar may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Qunar’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s goals and strategies; its future business development, financial condition and results of operations; the expected growth of the online travel markets in China; the Company’s expectations regarding demand for and market acceptance of its products and services; its expectations regarding our relationships with users and travel service providers; its plans to invest in the technology platform; competition in our industry; fluctuations in general economic and business conditions in China; and relevant government policies and regulations relating to our industry. Further information regarding these and other risks is included in our prospectus and other documents filed with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Qunar undertakes no duty to update such information, except as required under applicable law.

About Qunar

Qunar is China’s leading mobile and online travel platform. With a commitment to building a travel ecosystem serving the entire travel industry value chain, Qunar is evolving the way people travel in a world increasingly enabled by technology. Qunar addresses the needs of Chinese travelers and travel service providers by efficiently matching industry supply and demand through its proprietary technologies. By providing technology infrastructure for travel service providers on mobile and online platforms, Qunar integrates and offers the most comprehensive selection of travel products and the most convenient means to complete desired transactions for Chinese travelers.

Qunar means “where to go” in Mandarin Chinese.

For more information, please visit http://ir.qunar.com.

CONTACT: For investor inquiries, please contact:

         Xiaolu Zhu
         Investor Relations
         Qunar Cayman Islands Limited
         Tel: +86-10-5760-3609
         Email: ir@qunar.com

(CYBR) To Present At Gartner Security & Risk Management Summit 2015

CyberArk (NASDAQ: CYBR), the company that protects organizations from cyber attacks that have made their way inside the network perimeter, today announced details of its participation at the Gartner Security & Risk Management Summit 2015 taking place June 8-11. The CyberArk session, “The Most Traveled Attack Route: Securing the Privileged Pathway,” will explain the role of privileged accounts in advanced attacks and how businesses can mitigate risk by properly securing and managing these powerful credentials.

In addition, at booth #845 CyberArk will demonstrate its Privileged Account Security Solution.

To view a video introduction to CyberArk Privileged Account Security Solution, please visit: https://www.youtube.com/watch?v=x_uFunHQ5mg.

To download the report, “Privileged Account Exploits Shift the Front Lines of Cyber Security,” visit www.cyberark.com/threat-report.

About CyberArk
CyberArk is the only security company focused on eliminating the most advanced cyber threats; those that use insider privileges to attack the heart of the enterprise. Dedicated to stopping attacks before they stop business, CyberArk proactively secures against cyber threats before attacks can escalate and do irreparable damage. The company is trusted by the world’s leading companies – including 40 percent of the Fortune 100 and 17 of the world’s top 20 banks – to protect their highest value information assets, infrastructure and applications. A global company, CyberArk is headquartered in Petach Tikvah, Israel, with U.S. headquarters located in Newton, MA. The company also has offices throughout EMEA and Asia-Pacific. To learn more about CyberArk, visit www.cyberark.com, read the company blog, http://www.cyberark.com/blog/, follow on Twitter @CyberArk or Facebook at https://www.facebook.com/CyberArk.

Copyright © 2015 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.

Media Relations:
fama PR
Lindsay Sollima, +1-617-986-5026
cyberark@famapr.com
or
CyberArk
Christy Lynch, +1-617-796-3210
press@cyberark.com
or
Investor Relations:
ICR
Staci Mortenson, +1-617-558-2132
IR@cyberark.com

(JASO) Receipt of “Going Private” Proposal at $9.69 Per ADS, $1.938 Per Ordinary Share

SHANGHAI, China, June 5, 2015  — JA Solar Holdings Co., Ltd. (Nasdaq:JASO) (the “Company”), one of the world’s largest manufacturers of high-performance solar power products, today announced that its board of directors (the “Board”) has received a preliminary non-binding proposal letter dated June 5, 2015 from Mr. Baofang Jin, its Chairman and Chief Executive Officer, and Jinglong Group Co., Ltd., a British Virgin Islands company of which Mr. Baofang Jin is the sole director (collectively, the “Buyer Group”), to acquire all of the outstanding shares of the Company not already owned by the Buyer Group in a going private transaction for US$9.69 per American Depositary Share (“ADS”, each ADS representing five ordinary shares) or US$1.938 per ordinary share in cash, subject to certain conditions. A copy of the proposal letter is attached hereto as Exhibit A.

The Board intends to form a special committee consisting of independent directors to consider this proposal. The Company cautions its shareholders and others considering trading in its securities that the Board just received the non-binding proposal and has not made any decisions with respect thereto. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.

About JA Solar Holdings Co., Ltd.

JA Solar Holdings Co., Ltd. is a leading manufacturer of high-performance solar power products that convert sunlight into electricity for residential, commercial, and utility-scale power generation. The Company is one of the world’s largest producers of solar power products. Its standard and high-efficiency product offerings are among the most powerful and cost-effective in the industry. The Company distributes products under its own brand and also produces on behalf of its clients. The Company shipped 3.1 GW of solar power products in 2014. JA Solar is headquartered in Shanghai, China, and maintains production facilities in Shanghai, as well as Hebei, Jiangsu and Anhui provinces.

For more information, please visit www.jasolar.com.

Contact:

Exhibit A

June 5, 2015

Dear Sirs:

I, Baofang Jin, Chairman and Chief Executive Officer of JA Solar Holdings Co., Ltd. (the “Company”), together with Jinglong Group Co., Ltd., a British Virgin Islands company of which I am the sole director (together, “we” or the “Buyer Group”), are pleased to submit this preliminary non-binding proposal to acquire all the outstanding ordinary shares (the “Shares”) of the Company not owned by the Buyer Group in a going-private transaction (the “Acquisition”). The Buyer Group currently beneficially owns approximately 15.6% of the Shares of the Company.

We believe that our proposal of US$1.938 in cash per Share, or US$9.69 in cash per American Depositary share of the Company (“ADS”, each representing 5 Shares), will provide a very attractive opportunity to the Company’s shareholders. This price represents a premium of approximately 20% to the Company’s closing price on June 4, 2015.

The terms and conditions upon which the Buyer Group is prepared to pursue the Acquisition are set forth below. We are confident that we can consummate the Acquisition as outlined in this letter.

1. Buyer. We intend to form an acquisition vehicle for the purpose of implementing the Acquisition. The Acquisition will be in the form of a merger of the Company with the acquisition vehicle.

2. Purchase Price. Our proposed consideration payable for the Shares acquired in the Acquisition will be US$1.938 per Share, or US$9.69 per ADS, in cash.

3. Financing. We intend to finance the Acquisition with a combination of debt and equity capital, and expect definitive commitments for the required debt and equity funding, subject to terms and conditions set forth therein, to be in place when the Definitive Agreement (as defined below) are signed.

4. Due Diligence. Parties providing financing will require a timely opportunity to conduct customary due diligence on the Company. We would like to ask the board of directors of the Company to accommodate such due diligence request and approve the provision of confidential information relating to the Company and its business to possible sources of equity and debt financing subject to a customary form of confidentiality agreement.

5. Definitive Agreements. We have engaged Skadden, Arps, Slate, Meagher & Flom LLP as the Buyer Group’s U.S. legal counsel. We are prepared to negotiate and finalize definitive agreements (the “Definitive Agreements”) expeditiously. This proposal is subject to execution of the Definitive Agreements. These documents will include provisions typical for transactions of this type.

6. Process. We believe that the Acquisition will provide superior value to the Company’s shareholders. We recognize of course that the Board will evaluate the proposed Acquisition independently before it can make its determination whether to endorse it. In considering the proposed Acquisition, you should be aware that we are interested only in acquiring the outstanding Shares the Buyer Group does not already own, and that we do not intend to sell our stake in the Company to a third party.

7. Confidentiality.   We will, as required by law, promptly file a Schedule 13D to disclose this letter. We are sure you will agree with us that it is in all of our interests to ensure that we proceed our discussions with respect to the Acquisition in a confidential manner, unless otherwise required by law, until we have executed the Definitive Agreements or terminated our discussions.

8. No Binding Commitment. This letter constitutes only a preliminary indication of our interest, and does not constitute any binding commitment with respect to the Acquisition. Such a commitment will result only from the execution of Definitive Agreements, and then will be on the terms provided in such documentation.

* * * * *

[Signature Page to Follow]

In closing, we would like to express our commitment to working together with you to bring this Acquisition to a successful and timely conclusion. Should you have any questions regarding this proposal, please do not hesitate to contact us. We look forward to speaking with you.

(BIOL) Features Groundbreaking Periodontal Protocol at Europerio 8

IRVINE, Calif. & LONDON, June 5, 2015  — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that its groundbreaking REPaiR periodontal protocol will be part of the scientific programme at Europerio 8, the world’s leading conference in periodontology and implant dentistry. The triennial conference organized by the European Federation of Periodontology takes place in London June 3 – 6, 2015 and attracts leading periodontists from more than 29 European countries.

REPaiR, Regenerative Er,Cr: YSGG Periodontitis Regimen, was developed by a team of leading periodontists from around the world in conjunction with BIOLASE and is supported by clinical research and meaningful patient outcomes. The REPaiR protocol is the first definitive step-by-step protocol for using an Er,Cr:YSGG laser to assist in the management of moderate and severe chronic periodontitis. REPaiR can be applied for total mouth periodontal treatment, or in a site-specific manner.

Presentation of the REPaiR protocol to members of the European Federation of Periodontology (EFP) supports the prestigious group’s awareness initiative. The EFP is strongly advocating that periodontal disease should be acknowledged as a major public health issue and for all dental and health professionals to act in the prevention, early diagnosis, and effective treatment of periodontal disease in order to combat the devastating oral and general health effects for the individual and society.

“What the EFP is doing in terms of leading the world in addressing periodontal disease is phenomenal. They have gone as far as creating a manifesto as a call to action to address this pressing global health concern. That I am able to participate and contribute to this movement for greater public health is extremely meaningful to me,” stated Samuel B. Low, D.D.S., M.S., M.Ed., Professor Emeritus, University of Florida, College of Dentistry, past President of the American Academy of Periodontology, and a principle developer of REPaiR.

Dr. Rana Al-Falaki, BDS, MFDS RCSI, MClinDent; MRD RCS, a leading London periodontist will be presenting the REPaiR protocol. Additionally, Dr. Samuel B. Low will be presenting on the topic entitled Innovative Closed Crown Lengthening with Micro Invasive Laser.

Compared to conventional methods employed to treat periodontitis, these speakers will present findings that support that the minimally invasive REPaiR laser protocol offers significant advantages, including:

• Reduces pain and discomfort compared to conventional treatment
• Promotes more rapid healing
• Promotes cementum mediated periodontal ligament new-attachment to the root surface in the absence of long junctional epithelium
• Expands treatment options for preserving tissue and bone

Visit BIOLASE at the Europerio meeting to learn more about how WaterLase iPlus 2.0 can help your practice grow with REPaiR.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer benefits and value to healthcare professionals and their patients. The Company’s proprietary laser products incorporate approximately 250 patented and 100 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 27,600 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

Rachel Moody
Director of Marketing
949-226-8114
rmoody@biolase.com

(VISN) Mobile Internet Affiliate Announces Financing Transaction Led by Baidu

VisionChina Media and Baidu to Collaborate on Urban Public Transit Wi-Fi Network Development

BEIJING, June 4, 2015  — VisionChina Media Inc. (“VisionChina Media” or the “Company”) (Nasdaq: VISN), China’s largest out-of-home digital television advertising network on mass transportation systems and the leading provider of urban mass transit Wi-Fi, today announced the signing of a definitive Equity Subscription Agreement (the “Agreement”) for approximately US$11.5 million of Series A equity for Shenzhen Qianhai VisionChina Mobile Interactive Co., Ltd. (“Qianhai Mobile”). Qianhai Mobile is a consolidated affiliate[1] of the Company engaged in the research, development and operation of mass transit Wi-Fi networks and the provision of mobile Internet value-added services in the PRC. The transaction was led by Beijing Baidu Netcom Science Technology Co., Ltd., a consolidated affiliate of Baidu Inc. (Nasdaq: BIDU) and also included Guangdong Zhongke Baiyun New Industry Venture Investment Co., Ltd. and Dongguan Zhongke Zhongguang Venture Investment Co., Ltd., both of which are reputable national private equity investors in the PRC. The transaction is subject to customary closing conditions.

As part of the transaction, Qianhai Mobile and Baidu have entered into a Business Cooperation Agreement to jointly develop and monetize mobile app distribution and other mobile passenger services powered by Baidu Map.

Mr. Limin Li, VisionChina Media’s Chairman and Chief Executive Officer commented, “This transaction represents another important milestone for our Company, and a significant step in our strategy to develop the largest transit-based Wi-Fi network in China. We are proud to have Baidu and other investors demonstrating confidence in our vision, business model and execution capabilities. We believe that our collaboration with Baidu will yield meaningful technology synergies and future monetization opportunities.”

Mr. Peter Fang, Senior Director of Baidu Corporate Development commented, “We are very impressed with VisionChina Media’s many years of experience operating the leading public transit-based media platform in China, and the Company’s ongoing transition to an Internet-focused business. We are excited about the opportunity to work with VisionChina Media to truly address the needs of urban commuters and realize the significant long-term value of the Company’s public transit Wi-Fi network.”

As of date of this press release, VisionChina Media, through its Qianhai Mobile affiliate, has secured exclusive concession rights for bus Wi-Fi services in 18 cities across China, including Shanghai, Shenzhen, Guangzhou and Tianjin, covering approximately 35,000 buses. Currently, Qianhai Mobile provides free Wi-Fi Internet services on approximately 15,000 buses under the brand name “VIFI,” spanning over 7.5 million commuters and providing over 3 million Wi-Fi service sessions per day. The Company will use the proceeds from this transaction to pursue additional concession rights and further expand its Wi-Fi network infrastructure to solidify its leading position in this market.

About Baidu

Baidu, Inc. is the leading Chinese language Internet search provider. As a technology-based media company, Baidu aims to provide the best and most equitable way for people to find what they’re looking for. In addition to serving individual Internet search users, Baidu provides an effective platform for businesses to reach potential customers. Baidu’s ADSs trade on the NASDAQ Global Select Market under the symbol “BIDU”. Currently, ten ADSs represent one Class A ordinary share.

About VisionChina Media Inc.

VisionChina Media Inc. (Nasdaq: VISN) operates an out-of-home advertising network on mass transportation systems, including buses and subways. As of December 31, 2014, VisionChina Media’s advertising network included 92,469 digital television displays on mass transportation systems in 19 of China’s economically prosperous cities, including Beijing, Guangzhou and Shenzhen, as secured by exclusive agency agreements or joint venture contract. VisionChina Media has the ability to deliver real-time, location-specific broadcasting, including news, stock quotes, weather and traffic reports, and other entertainment programming. For more information, please visit http://www.visionchina.cn.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates” and similar statements. Among other things, the quotations from management in this press release contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1 and its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For investor and media inquiries, please contact:

In China:
Ms. Shuning Yi
Investor Relations Department
VisionChina Media Inc.
Tel: +86-134-2090-9426
E-mail: shuning.yi@visionchina.cn

In the United States:
The Piacente Group, Inc.
Mr. Glenn Garmont
Tel: +1-212-481-2050
E-mail: visionchina@tpg-ir.com

(GEVO) Jet Fuel to be Used in First Ever Test Flight Flown on Fuel Derived From Wood Waste

Gevo’s Patented Technology to Make Jet Fuel From Cellulosic Wood Waste Will be Used in Demonstration Flight Sponsored by Northwest Advanced Renewables Alliance and Major North American Airline

ENGLEWOOD, Colo., June 4, 2015  — Gevo, Inc. (Nasdaq:GEVO) announced today a breakthrough to its fermentation technology that will allow it to produce isobutanol from cellulosic feedstocks such as wood waste which can then be converted into Gevo’s alcohol-to-jet fuel.

Gevo currently makes isobutanol from corn at its plant in Luverne, Minn., but its process has always had the flexibility to adapt to other feedstocks. The process announced today uses forest residuals – the wood scraps that are left over from logging operations – providing a value creating recycling opportunity for waste wood that is traditionally left in the forest, potentially becoming a forest fire hazard. The company has previously announced the testing and use of its alcohol-to-jet fuel derived from its corn-based isobutanol in conjunction with major airline partners and the U.S. military.

Gevo has adapted its patented Gevo Integrated Fermentation Technology® (GIFT®) to convert the cellulosic sugars from wood into renewable isobutanol. Gevo then uses its patented hydrocarbon technology to convert the cellulosic isobutanol into alcohol-to-jet-synthetic paraffinic kerosene (ATJ-SPK) fuel.

The company’s cellulosic isobutanol production will be conducted at a demonstration facility in St. Joseph, MO, that the company jointly operates with ICM Inc. The ATJ-SPK will be produced in Silsbee, TX, at the demonstration facility the company operates with South Hampton Resources.

Gevo is a member of the Northwest Advanced Renewables Alliance (NARA) and is providing the organization with technology to enable the commercial scale processing of cellulosic sugars from wood waste into valuable products. The cellulosic jet fuel made using Gevo’s technologies will be used in a 1,000-gallon renewable fuel demonstration test flight that NARA announced yesterday. Gevo’s isobutanol and ATJ-SPK technologies are both planned to be licensed by NARA as part of this project.

“There are significant economic and environmental benefits of renewable jet fuel, which makes it a great market for Gevo. This announcement demonstrates the flexibility of our technology and reinforces our technology leadership,” said Dr. Pat Gruber, Chief Executive Officer of Gevo, Inc. “The next two milestones for renewable jet fuel are the approval by ASTM and the scheduled commercial test flights. Our team is actively engaged in both of these activities.”

“We’re encouraged by Gevo’s work with the NARA team in converting Pacific Northwest forest residual biomass into jet fuel, and look forward to working with them on this test flight and in the next phases of the commercialization of this technology,” said Ralph Cavalieri, Director of NARA.

NARA is a five-year project supported by the U.S. Department of Agriculture, National Institute of Food and Agriculture, and is comprised of 22 member organizations from industry, academia and government laboratories. Its mission is to facilitate development of biojet and bioproduct industries in the Pacific Northwest using forest residuals that would otherwise become waste products. A key task of the project is to evaluate the economic, environmental and societal benefits and impacts associated with such developments.

About Gevo

Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo’s strategy is to commercialize bio-based alternatives to petroleum-based products to allow for the optimization of fermentation facilities’ assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, MN. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, TX, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo has a marquee list of partners including The Coca-Cola Company, Toray Industries Inc. and Total SA, among others. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, statements regarding the expected effect of the new agreement on Gevo’s working capital and its corn purchasing capabilities and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2014, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Gevo.

CONTACT: Media Contact
         Karen Freedman / David Rodewald
         The David James Agency, LLC
         +1 805-494-9508
         gevo@davidjamesagency.com

         Investor Contact:
         Mike Willis
         Gevo, Inc.
         T: (720) 267-8636
         mwillis@gevo.com

(ANTH) Phase 2b PEARL-SC Blisibimod Study

HAYWARD, Calif., June 4, 2015  — Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs, today announced that additional data from its Phase 2b PEARL-SC study will be presented in a poster at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Rome, Italy.

As part of a guided poster tour on June 6^th, 2015, Dr. Michelle Petri, Director of the Hopkins Lupus Center at Johns Hopkins University, will present breaking data on the impact of treatment with blisibimod on patient-reported fatigue and improvement in disease biomarkers.

“Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus”

Treatment with blisibimod was associated with statistically significant and clinically meaningful improvements in patient-reported fatigue, as measured by the FACIT-fatigue scale, over a similar time course as the SRI and SLE biomarker response rates.  These effects were most evident at the highest dose of blisibimod (200mg QW). The FACIT-fatigue scale is a measure of health-related quality of life with a specific focus on fatigue, tiredness and weakness. For more information on the CHABLIS-SC1 trial, please visit https://clinicaltrials.gov/ct2/show/NCT01395745?term=chablis&rank=1.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as “estimate,” “intend,” “anticipate,” “believe,” “plan,” “goal,” “expect,” “project,” or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera’s expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera’s public filings with the SEC, including Anthera’s Annual Report on Form 10-Q for the year ended March 31, 2015. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc.,
         dlutz@anthera.com or 510.856.5598

(NVET) Positive Top-Line Results From Efficacy Study of NV-02

DUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015  — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including osteoarthritis, in cats. Additionally, Nexvet received positive data from a high-dose pilot safety study of NV-02 in cats, which was conducted by an independent contract research organization.

The primary efficacy endpoints of the POC study were measured using:

• Owner-assessed Client Specific Outcome Measures (CSOM), which measures changes in certain patient behaviors, and
• Collar-mounted accelerometer data, which measures overall patient activity levels

These measurements were performed over nine weeks after administration in both the treatment and placebo groups. In both the POC and safety studies, the feline subjects were dosed with a single subcutaneous injection of NV-02.

The top-line outcomes from the two studies are:

• A statistically significant clinical improvement from baseline was observed in CSOM scores taken three weeks after treatment, when compared with placebo (p<0.05) in the POC study
• A statistically significant improvement in activity was measured with accelerometer data, when compared to placebo from weeks two to five following administration (p<0.05) in the POC study
• No adverse events were observed at the doses tested in the POC study, nor in the separate safety study where cats were treated with NV-02 at more than 10 times the highest dose used in the POC study.

“Veterinarians emphasize the need for safer and more effective therapies in the area of feline chronic pain management, so we are delighted with these results for NV-02. These two studies have generated a dataset that will be used to design further studies of NV-02 in this area of significant unmet medical need,” said Dr. Mark Heffernan, Chief Executive Officer of Nexvet.

The POC study was a randomized, double-blinded, placebo-controlled efficacy study of 32 client-owned cats with DJD and was conducted at the Comparative Pain Research Laboratory of the North Carolina State University College of Veterinary Medicine. Dr. Margaret Gruen and Professor Duncan Lascelles served as the primary investigators for this trial.

In previous studies, NV-02 has also been found to be safe and well tolerated when administered subcutaneously or intravenously and to have a prolonged elimination half-life after a single injection. Repeated administration did not induce a neutralizing antibody response in a previous study of four cats, indicating the feline immune system did not identify NV-02 as a ‘foreign’ protein, an important step in successfully designing a biologic drug for repeated administration. In another previous study, NV-02 was also shown to reduce lameness scores in an acute feline model of inflammatory pain, with efficacy comparable to meloxicam, a standard NSAID used in acute feline pain management.

Feline chronic pain management is an area of critical unmet need in veterinary medicine. In the United States, there are no drugs approved for chronic pain management in cats, and only one is approved for this use in Europe. This is especially concerning when clinical studies indicate a majority of cats show radiographic evidence associated with DJD, the progression of which is generally associated with increasing pain and disability.

The current leading class of drug for acute (short-term) pain relief in dogs and cats are non-steroidal anti-inflammatory drugs (NSAIDs). In the United States, NSAIDs are not approved for chronic use in cats due to concerns over toxic side effects, which include gastrointestinal effects and damage to the kidneys or liver. Nexvet’s studies suggest that mAbs like NV-02, which do not interact with the unique biochemistry of cats in the same way as NSAIDs, may provide an effective and safe alternative for cats.

“These results provide further evidence supporting both NGF as a target for controlling pain in feline DJD, and PETization as a robust platform for translating mAbs between species. mAbs have long half-lives in patients and, unlike NSAIDs, are metabolized into simple amino acids and sugars. These factors give mAbs a favorable product profile for long-term administration in cats,” commented Dr. David Gearing, Chief Scientific Officer of Nexvet.

Dr. Gearing will be presenting development data regarding NV-02, including the top-line results announced today, at the American College of Veterinary Internal Medicine Forum in Indianapolis, Indiana on June 5, 2015 at 9:00AM. The presentation is entitled A Feline-Specific Anti-NGF Antibody is Safe and Effective for the Alleviation of Inflammatory Pain in Cats.

Nexvet will continue to analyze the large set of data generated from these studies and expects to outline next steps for its NV-02 clinical development program in the third calendar quarter of 2015.

About the cat chronic pain market

According to the 2015-2016 American Pet Products Association National Pet Owners Survey and the European Pet Food Industry Federation’s Facts and Figures 2012, there are approximately 85.8 million pet cats in the United States and approximately 66.5 million pet cats in Europe.

Various clinical studies have indicated that a majority of cats show radiographic evidence of DJD. DJD is a term encompassing various conditions including osteoarthritis, although the two terms are often used interchangeably.

In the United States, there are no drugs approved for chronic pain management in cats. In one leading veterinary industry report on pain management by Brakke Consulting, released in April 2015, only 24% of U.S. veterinarians surveyed were satisfied with pain management choices for cats. Of the 76% of veterinarians who were dissatisfied, 50% said they needed drugs for long-term use in cats, and 43% said they needed safer drugs.

Nexvet believes the introduction of a safe and effective pain management product class for cats, such as anti-NGF mAbs, will result in significant sales, similar to the growth dynamic observed when NSAIDs were introduced for the canine pain market in the mid-1990s. In the United States alone, sales of canine pain management products increased from less than $10 million in 1995 to approximately $262 million in 2013, representing a compound annual growth rate of approximately 12%, following the introduction of carprofen, an NSAID, in 1996.

In a proprietary report commissioned by Nexvet in December 2013 surveying 390 veterinarians in the United States, United Kingdom, France and Germany, between 86% and 98% of veterinarians surveyed would use a product such as NV-02 for the treatment of chronic pain in cats.

Forward-Looking Statements

All statements in this press release other than statements of historical fact are forward-looking statements, including statements regarding the results or time for completion of any clinical studies, future results of operations and financial position, business strategy, prospective products, product approvals, timing and likelihood of success, market opportunities, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to materially differ from the results, performance or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “expect,” “may,” “objective,” “plan,” “will” or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future results, performance or achievements. Factors that could cause actual results, performance or achievements to differ materially include those summarized under Risk Factors in our reports on Forms 10-Q and the other documents we file from time to time with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements. We undertake no obligation to revise or update these forward-looking statements, except as required by law.

About Nexvet (www.nexvet.com)

Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly create monoclonal antibodies (“mAbs”) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

CONTACT: Further information:

         Investors
         Candice Knoll
         Blueprint Life Science Group
         +1 415-375-3340 Ext. 105
         cknoll@bplifescience.com

         Media
         Lynn Granito
         Berry & Company Public Relations
         +1 212-253-8881
         lgranito@berrypr.com

(LTBR) South Korea Grants Lightbridge Key Patent for Metallic Nuclear Fuel Design

MCLEAN, Va., June 4, 2015  — Lightbridge Corporation (Nasdaq:LTBR), a leading innovator of nuclear fuel designs and provider of nuclear energy consulting services, today announced that the Korean Intellectual Property Office has approved and issued to Lightbridge a key patent covering the Company’s multi-lobed metallic fuel rod design and fuel assemblies. Patent No. 10-151116 – “Nuclear Reactor (Variants), Fuel Assembly Consisting of Driver-Breeding Modules for a Nuclear Reactor (Variants) and a Fuel Cell for a Fuel Assembly” – expands international protection of Lightbridge’s proprietary fuel technology with indicated benefits of enhanced reactor safety and improved operating economics.

“The South Korean patent is another important milestone in the development of our fuel assembly designs for existing and new build pressurized water reactors,” said Seth Grae, Lightbridge President and Chief Executive Officer. “Korea represents a significant potential market for Lightbridge metallic fuel with 24 operating pressurized water reactors and an additional 12 reactors either under construction or planned by 2035, according to the most current data compiled by the World Nuclear Association.”

South Korea also is an active exporter of nuclear power reactors, marketing its units in the Middle East, North Africa and Southeast Asia. The South Korean Ministry of Trade, Industry and Energy aims to export 80 reactors worth $400 billion by 2030, the association reports.

The advantages of Lightbridge’s metallic fuel design were confirmed in independent third-party analyses published in 2012 and 2013, Grae added. These reports, which include a peer-reviewed article published in Nuclear Technology, are available for download at http://ir.ltbridge.com/. He said the indicated benefits of Lightbridge’s fuel include:

• A 1,000°C reduction in average fuel operating temperature, compared to conventional uranium dioxide pellet fuel, resulting in dramatic safety improvements;
• Improved heat transfer and fluid flow, increased structural strength, and improved performance during transients and accidents;
• 10% more power and longer fuel cycles or up to 17% more power with the same fuel cycle length for existing pressurized water reactors (PWRs);
• Up to 30% more power with the same fuel cycle length for new build PWRs;
• Increased revenue and improved profit margins for existing nuclear power units;
• Lower total levelized cost per kilowatt-hour for new build reactors;
• Increased competitiveness of nuclear power versus fossil or renewable energy sources;

The commercial nuclear energy industry is projected to grow rapidly at a time of rising global demand for reliable, carbon-free, base load electric power. There are currently 437 operable civil nuclear reactors in 30 countries around the world, with 66 reactors under construction and 490 on order, planned or proposed, according to the World Nuclear Association. By 2040, the International Energy Agency projects a 58% increase in nuclear capacity from a combination of power uprates and reactor construction.

In April 2015, the nuclear fuel managers at Dominion Generation (NYSE:D), Duke Energy (NYSE:DUK), Exelon Generation (NYSE:EXC) and Southern Company (NYSE:SO) asked the U.S. Nuclear Regulatory Commission (NRC) to prepare to review Lightbridge’s fuel design, in advance of an expected application in 2017 to use the Company’s fuel in a U.S. reactor as early as 2020. The NRC relies on communications from U.S. utilities to adjust Commission staffing levels and budgets in anticipation of regulatory review of licensing applications.

“This formal expression of interest by major U.S. utilities is the strongest endorsement to date of Lightbridge fuel by potential customers,” Grae said. The Commission posted the utilities’ expression of interest in Lightbridge’s fuel and supporting documents on its official web site at http://pbadupws.nrc.gov/docs/ML1513/ML15134A092.pdf

About Lightbridge Corporation

Lightbridge is a nuclear energy company based in McLean, Virginia. The Company develops proprietary next generation nuclear fuel technologies for current and future nuclear reactor systems. Lightbridge’s breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.

Important milestones achieved by Lightbridge in 2014 include U.S. Patent and Trademark Office (USPTO) approval and issuance in February of the key patent (#8,654,917) covering the Company’s multi-lobed metallic fuel rod design and fuel assemblies. In July, the Company was issued its first international patent on its fuel rod design by the Commonwealth of Australia Patents Office.  A provisional patent application was filed in the U.S. relating to use of the Company’s metallic fuel in CANDU-type power reactors.

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Forward Looking Statements

This news release contains statements that are forward-looking in nature within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s competitive position and product and service offerings. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to, the degree of market adoption of the Company’s product and service offerings; market competition; dependence on strategic partners; and the Company’s ability to manage its business effectively in a rapidly evolving market. Certain of these and other risks are set forth in more detail in Lightbridge’s filings with the Securities and Exchange Commission. Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise.

CONTACT: Gary Sharpe
         Investor Relations and Corporate Communications
         Lightbridge Corporation
         1-571-730-1213
         gsharpe@ltbridge.com

(NETE) Launches Payment Processing in Kazakhstan; Signs Premier Online Events Ticketer

Integration With Kazakhstan’s Largest Bank Opens New Market With 60 Million Population

(CPXX) Enrollment is Complete in CPX-351 Phase 2 Study

– Encouraging response rate achieved; including patients with high-risk (secondary) AML (the Phase 3 study population), de novo AML, relapsed AML, and relapsed ALL –

EWING, N.J., June 3, 2015  — Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that enrollment is complete in a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of CPX-351 (cytarabine:daunorubicin) Liposome Injection on cardiac repolarization in adult patients with acute hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS).

The open-label, single-arm, Phase 2 study is a thorough PK/PD assessment designed to: (1) measure the effects of CPX-351 on cardiac repolarization following the first induction cycle of CPX-351, and (2) correlate changes in cardiac repolarization with plasma pharmacokinetic data for cytarabine and daunorubicin and their metabolites. The study began enrolling patients in August 2014.  Each patient received a first induction of CPX-351 on days 1, 3 and 5 and, if necessary, a second induction for patients with reduced leukemia/MDS burden not yet achieving a disease-free state. Responding patients were eligible for up to four consolidation courses. Analysis of treatment impact on cardiac electrophysiology, as measured by the QTc interval, and PK assessments were performed following the first induction course.

The study enrolled patients with newly diagnosed de novo and high-risk (secondary) AML, relapsed/refractory AML and relapsed ALL.  Fifteen of the 26 patients enrolled are evaluable for response at this time. Six of the 15 patients responded to CPX-351 (defined as CR-complete response or CRi-complete response with incomplete hematologic recovery) including 2 of 3 patients (67%) with high-risk (secondary) AML, the study population of the ongoing Phase 3 trial. Responses were also seen in patients with de novo AML, relapsed AML, and relapsed ALL.

“We are happy to report that this study confirms the broad activity of CPX-351 in multiple populations of acute leukemia patients,” said Tara Lin, M.D., Assistant Professor of Medicine at The University of Kansas Cancer Center, the lead investigator of this study, “and will report cardiac repolarization and pharmacokinetic data necessary for the registration of CPX-351 later this year.”

The Phase 2 study was conducted to support the U.S. Food and Drug Administration (FDA) requirements of a New Drug Application (NDA) for CPX-351.  Our Phase 3 study comparing CPX-351 to the current standard of care, known as 7+3, is being conducted in patients with high-risk (secondary) AML.  The Phase 3 study completed enrollment in November 2014.  Initial data from a secondary endpoint, induction response rate, is expected by the end of June 2015.  The primary endpoint data, of overall survival, is expected in the first quarter of 2016.

“We continue to work expeditiously to bring CPX-351 before the FDA as a potential new treatment option for patients with acute hematologic malignancies,” said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals. “Clinical pharmacology studies are required by the FDA for new drugs in development, so we are pleased to have completed enrollment in this Phase 2 study to support a NDA submission for CPX-351. We expect to report top-line results from this study by the end of the year.”

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity.  CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor.  Celator’s pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory.  The company is advancing the CombiPlex platform and broadening its application to include molecularly targeted therapies and epigenetic modulators.

For more information, please visit Celator’s website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Forward-Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the safety,  efficacy and therapeutic potential of CPX-351, the availability of data from clinical studies, our expectations regarding regulatory approvals and our expectations regarding our research and development programs, expanding our pipeline and advancing our CombiPlex platform. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of clinical studies, whether the final results of our clinical studies will be supportive of regulatory approval to market CPX-351 and other matters that could affect the commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Celator in general, see Celator’s Form 10-K for the year ended December 31, 2014 and other filings by Celator with the U.S. Securities and Exchange Commission.

(HNSN) Magellan System, World’s First Series in Robotic Cancer Treatment

(STCK) & BMC to Merge

Combination Enhances Geographic Reach in Key Growth Markets Across the United States and Expands Product and Service Offerings

Transaction Expected to Result in Annual Synergies of $30 to $40 Million and to Be Accretive to Stock Building Supply’s Earnings per Share in the First Year Following Closing

RALEIGH, N.C. and ATLANTA, June 3, 2015  — Stock Building Supply Holdings, Inc. (Nasdaq:STCK) (“Stock Building Supply”) and Building Materials Holding Corporation (“BMC”), two leading building materials and solutions providers to professional contractors, today announced the signing of a definitive merger agreement under which the two companies will combine in an all-stock transaction. The combined company is expected to have an implied pro forma enterprise value of $1.5 billion based on Stock Building Supply’s closing price on June 2^nd.

The transaction will create a premier provider of lumber, diversified building products and construction services with over $2.7 billion in pro forma 2014 revenues and enhanced product and service offerings. The combined company will have expanded geographic reach in attractive, fast-growing regions across the United States, innovative technology capabilities and deep industry expertise to drive profitable growth and provide leading customer service.

Among the numerous benefits the combined company is expected to bring to all stakeholders include:

• An enhanced growth, margin and return profile.
• A strong balance sheet and significant cash flow to support long-term strategic growth in a highly fragmented industry.
• Significant and achievable synergy potential rising to $30 – $40 million annually within two years.
• An expanded footprint from 21 to 42 metropolitan areas, principally in the fast-growing South and West regions.
• A shared deep commitment to providing solutions to customers while delivering a broad range of quality products and services.
• Projected accretion to Stock Building Supply’s earnings per share in the first full year following close of the transaction.

“We expect this compelling strategic merger will provide significant benefits for customers, shareholders, suppliers and associates of both companies,” said Jeff Rea, President and Chief Executive Officer of Stock Building Supply. “The continuing recovery of the U.S. housing market is expected to generate strong demand for building materials, services and solutions, and together we believe BMC and Stock Building Supply are better positioned to capitalize on this opportunity. Upon close of this transaction, I look forward to continuing on our board to support the combined company and have great faith in the combined leadership team’s ability to create significant shareholder value by accelerating the implementation of our common strategies.”

Peter Alexander, BMC’s Chief Executive Officer, said, “We are very pleased to be uniting two leading companies with complementary strategies, products and services; a shared commitment to superior customer experiences; strong internal performance-based cultures and operations in high-demand geographies. The combination of our two highly complementary platforms will enhance our ability to provide customers with best-in-class products and services across an expanded geographic footprint. We have great respect for what the team at Stock Building Supply has accomplished and upon close of this transaction, I look forward to leading the combined team as we enter the next exciting phase of our transition and the ability to fund our growth.”

Transaction Terms

Under the terms of the agreement, which has been unanimously approved by the Board of Directors of both companies, BMC shareholders will receive 0.5231 newly issued Stock Building Supply shares for each BMC share. Upon the closing of the transaction, BMC shareholders will own approximately 60% of the merged entity, with Stock Building Supply shareholders owning approximately 40%. The transaction is structured to be tax-free to the shareholders of both companies, and is expected to close in the fourth quarter of 2015, subject to approval by both Stock Building Supply and BMC shareholders and typical regulatory clearances.

Funds affiliated with Davidson Kempner Capital Management LP, Ravenswood Investment Management and MFP Partners, L.P., which collectively own approximately 52% of BMC’s outstanding common stock, and funds affiliated with Gores, Stock Building Supply’s largest shareholder, which own approximately 38% of Stock Building Supply’s outstanding common stock, have each agreed to vote in favor of and fully support the transaction.

Proven Leadership Team

Upon closing of the transaction, BMC Chief Executive Officer Peter Alexander will serve as Chief Executive Officer of the combined company and will be a member of the Board of Directors. Jeff Rea, the current Stock Building Supply President and Chief Executive Officer, will remain a member of the Board of Directors of the company. The new leadership team is expected to include representatives of both companies, with current Stock Building Supply Executive Vice President and Chief Financial Officer Jim Major assuming the role of Chief Financial Officer, Stock Building Supply Executive Vice President and Chief Operating Officer Bryan Yeazel assuming the position of Chief Administrative Officer and General Counsel and current BMC Chief Integration Leader Tony Genito leading the integration of the two businesses. In addition to Mr. Alexander and Mr. Rea, the remainder of the combined company’s Board of Directors will be comprised wholly of independent directors, including representatives from each company’s current board. The combined company will be headquartered in Atlanta, GA and will have its main operating center in Raleigh, NC and plans to continue to operate under both the Stock Building Supply and BMC names in their respective local markets.

Mr. Alexander possesses 21 years of experience in the distribution industry. He joined BMC as a director in January 2010 and subsequently was appointed Chief Executive Officer in August 2010. He has led BMC as it has grown into one of the industry-leading providers of residential building products and construction services in fast-growing regions throughout the U.S. Prior to BMC, Mr. Alexander served as President and Chief Executive Officer at ORCO Construction Distribution. He previously served in leadership roles at several companies in the technology, retail/distribution and service industries, including GE Capital, ComputerLand (now Vanstar), Premiere Global Services and Coast to Coast Hardware.

Strategic Benefits

The transaction is expected to result in a combined company that is better positioned to accelerate its growth and deliver significant value to all stakeholders as it continues to accelerate both Stock Building Supply’s and BMC’s existing strategies of capitalizing on expansion opportunities in a fragmented building materials market to strengthen its long-term growth position.

BMC and Stock Building Supply both possess complementary product and service offerings, similar operating principles and a customer service focus that will enable a smooth and efficient integration. The combined company will have a strong position in growth markets across 17 states. Together, the companies will also provide a comprehensive portfolio of building materials, including millwork and structural frame manufacturing capabilities, consultative showrooms and value-added installation management that supports customers’ needs for turnkey solutions. Additionally, BMC’s businesses will provide expanded opportunity to introduce Stock Building Supply’s industry-leading eBusiness platform.

Customers of BMC and Stock Building Supply will continue to experience the same proactive, high-touch service and quality product offerings they have come to rely upon, while receiving the benefits of an expanded product line and stronger technology platform. In addition, the combined company plans to continue to focus on building a high performance, teamwork-driven culture that will offer increased opportunities to its employees as the company accelerates its growth trajectory.

Financing

In connection with the transaction, Stock Building Supply and BMC have received a joint commitment from Wells Fargo Bank, N.A. and Goldman Sachs Bank USA, contingent upon the closing of the transaction, to consolidate and upsize existing revolving Asset Based Loan facilities to $450 million for use by the combined company. Available funds will be used to refinance outstanding balances under the current revolving credit facilities, support up to $75 million in letters of credit, and fund transaction costs, general corporate purposes and working capital. Additionally, $250 million of existing BMC Senior Secured Notes maturing in 2018 are expected to remain outstanding. The closing of the transaction is not subject to financing conditions.

Advisors

Barclays Capital Inc. is serving as financial advisor to Stock Building Supply, with Hunton & Williams LLP serving as legal counsel. Goldman, Sachs & Co. is serving as financial advisor and Kirkland & Ellis LLP is serving as legal counsel to BMC.

Conference Call

Stock Building Supply and BMC will host a conference call today, June 3, 2015 at 9:00 a.m. (Eastern Time) and will simultaneously broadcast it live over the Internet. The conference call can be accessed by dialing 1-877-407-0784 (domestic) or 1-201-689-8560 (international). An investor presentation, to be reviewed during the conference call, can be accessed via Stock Building Supply’s investor relations website at ir.stocksupply.com. A telephonic replay of the conference call will be available immediately after the call and can be accessed by dialing 1-877-870-5176, or for international callers, 1-858-384-5517. The passcode for the live call and the replay is 13611438. The live webcast and archived replay can be accessed on Stock Building Supply’s investor relations website at ir.stocksupply.com. The online archive of the webcast will be available for approximately 90 days.

About Stock Building Supply

Stock Building Supply operates in 21 metropolitan areas in 14 states primarily in the South and West regions of the United States (as defined by the U.S. Census Bureau). Today, we serve our customers from 68 strategically located facilities. We offer a broad range of products, including lumber and lumber sheet goods, millwork, doors, flooring, windows, structural components, engineered wood products, trusses, wall panels and other exterior products. Our customer base includes production homebuilders, custom homebuilders and remodeling contractors.

About BMC

BMC, headquartered in Atlanta, Georgia, is a leading provider of residential building products and construction services to professional builders and contractors in the Western United States, Texas and North Carolina. The company has 38 lumber yards, 18 truss manufacturing facilities, 23 millwork operations and 3 Design Centers in 11 of the top 25 single-family construction markets.

Forward-Looking Statements

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words or phrases such as “may,” “might,” “predict,” “future,” “seek to,” “assume,” “goal,” “objective,” “continue,” “will,” “could,” “should,” “would,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “prospects,” “potential” and “forecast,” or the negative of such terms and other words, terms and phrases of similar meaning. Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties. Stock Building Supply cautions readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. Such forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving BMC and Stock Building Supply, including future financial and operating results, Stock Building Supply’s or BMC’s plans, objectives, expectations and intentions, the expected timing of completion of the transaction, and other statements that are not historical facts. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties relating to: the ability to obtain the requisite BMC and Stock Building Supply shareholder approvals; the risk that Stock Building Supply or BMC may be unable to obtain governmental and regulatory approvals required for the merger, or required governmental and regulatory approvals may delay the merger or result in the imposition of conditions that could cause the parties to abandon the merger; the risk that a condition to closing of the merger may not be satisfied; the timing to consummate the proposed merger; the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; the diversion of management time on merger-related issues; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; and other factors discussed or referred to in the “Risk Factors” section of Stock Building Supply’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and our subsequent filings with the SEC. These risk factors, as well as other risks associated with the merger, will be more fully discussed in the Registration Statement and the Proxy/Consent Solicitation Statement/Prospectus (as defined below). All such factors are difficult to predict and are beyond Stock Building Supply and BMC’s control.  All forward-looking statements attributable to Stock Building Supply or persons acting on Stock Building Supply’s behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and Stock Building Supply and BMC undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

The information in this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

The proposed transaction involving Stock Building Supply and BMC will be submitted to the respective stockholders of Stock Building Supply and BMC for their consideration. In connection with the merger and special meeting of Stock Building Supply’s stockholders, Stock Building Supply expects to file with the SEC a registration statement on Form S-4 (the “Registration Statement”) that will include a proxy statement/consent solicitation/prospectus (the “Proxy/Consent Solicitation Statement/Prospectus”). The definitive Registration Statement and the Proxy/Consent Solicitation Statement/Prospectus will contain important information about the merger, the merger agreement and related matters. This communication may be deemed to be solicitation material in respect of the proposed transaction between BMC and Stock Building Supply. This communication is not a substitute for the Registration Statement, Proxy/Consent Solicitation/Prospectus or any other documents that Stock Building Supply or BMC may file with the SEC or send to shareholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF STOCK BUILDING SUPPLY AND BMC ARE URGED AND ADVISED TO READ THE REGISTRATION STATEMENT AND THE PROXY/CONSENT SOLICITATION STATEMENT/PROSPECTUS CAREFULLY WHEN THEY BECOME AVAILABLE, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC AND ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. The Registration Statement, the Proxy/Consent Solicitation Statement/Prospectus and any other documents filed or furnished by Stock Building Supply with the SEC may be obtained free of charge at the SEC’s website (www.sec.gov). The Registration Statement, the Proxy/Consent Solicitation Statement/Prospectus and other relevant documents will also be available to security holders, without charge, from Stock Building Supply by going to its investor relations page on its corporate website at http://ir.stocksupply.com or from BMC by directing a request to Paul Street, Corporate Secretary of BMC, via email or telephone (paul.street@buildwithbmc.com, (208) 331-4300).

Participants in the Merger Solicitation

Stock Building Supply, BMC, their respective directors and certain of their executive officers and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Stock Building Supply is set forth in the proxy statement for Stock Building Supply’s 2015 Annual Meeting of Stockholders, which was filed with the SEC on April 30, 2015. Information about the directors and executive officers of BMC and more detailed information regarding the identity of all potential participants, and their direct and indirect interests, by security holdings or otherwise, will be set forth in the Registration Statement and the Proxy/Consent Solicitation Statement/Prospectus. Investors may obtain additional information regarding the interests of such participants by reading the Registration Statement and the Proxy/Consent Solicitation Statement/Prospectus when they become available. You may obtain a free copy of the proxy statement for Stock Building Supply’s 2015 Annual Meeting of Stockholders by going to its investor relations page on its corporate website at http://ir.stocksupply.com. You may obtain free copies of the Registration Statement, the Proxy/Consent Solicitation Statement/Prospectus and other relevant documents as described in the preceding paragraph.

CONTACT: Stock Building Supply:

         Investor Relations
         Mark Necaise, Stock Building Supply
         (919) 431-1021

         Media Relations
         Tom Johnson / Dana Gorman / Kate Schneiderman,
         The Abernathy MacGregor Group
         (212) 371-5999

         BMC:

         Investor Relations
         Paul Street, BMC
         (208) 331-4381

         Media Relations
         Michael Freitag / Sharon Stern / Leigh Parrish
         Joele Frank, Wilkinson Brimmer Katcher
         (212) 355-4449

(VBIV) eVLP Platform Data Showcasing Hep-C Vaccine Functionality

CAMBRIDGE, Mass., June 3, 2015  — VBI Vaccines (Nasdaq:VBIV) (“VBI”) delivered a presentation, Enveloped Virus-Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine, today at the World Vaccine Congress Asia. The event was held in Singapore at the Suntec Singapore Convention & Exhibition Centre.

A synopsis of the presentation, which was delivered by Jeff Baxter, VBI’s President and CEO, is available here: http://www.vbivaccines.com/wire/wvc-asia-2015

VBI’s Hepatitis C (“HCV”) vaccine candidate leverages the company’s eVLP vaccine platform, which enables the development of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that are designed to closely resemble the structure of viruses. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone.

VBI’s eVLP vaccine platform has been used to develop a Hepatitis C vaccine candidate that may be capable of eliciting broadly reactive neutralizing antibodies against multiple genotypes of HCV. This is a critical issue for HCV, as the virus is characterized by multiple, geographically distinct genotypes. Addressing the genetic diversity of the Hepatitis C virus may provide an advantage in developing successful antiviral regimens or therapeutic vaccines. In addition, VBI believes its HCV vaccine candidate may be capable of replacing interferon when used in combination with standard antivirals.

“VBI has previously demonstrated strong cross-reactive neutralizing antibody responses against multiple genotypes of HCV in monkeys,” said Mr. Baxter. “Based on this data, we believe our HCV vaccine candidate has the potential to be a promising and safe component of HCV treatment regimens, especially in areas where the transmission of Hepatitis C has not yet been adequately addressed by the existing field of approved and available drugs.”

Now in its eighth year, the World Vaccine Congress Asia is attended by decision makers from across the Asia Pacific region including leading research institutions, government regulators, and life sciences companies. To learn more, visit: http://bit.ly/wvc-asia-2015

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus. VBI’s lead eVLP asset is a prophylactic Cytomegalovirus (“CMV”) vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.

Website Home: http://www.vbivaccines.com/

News and Insights: http://www.vbivaccines.com/wire/

Investors: http://ir.vbivaccines.com/

Forward-Looking Statement Disclosure

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of VBI. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to VBI cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, VBI will not obtain appropriate or necessary governmental approvals to market these or other potential products, VBI may not be able to obtain anticipated funding for its development projects or other needed funding, and VBI may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and VBI does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

More detailed information about VBI and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in VBI’s filings with the Securities and Exchange Commission (the “Commission”). VBI urges investors and security holders to read those documents free of charge at the Commission’s Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from VBI. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, VBI undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

CONTACT: Company Contact

         Perri Maduri, Communications Executive
         Phone: (617) 830-3031 x124
         Email: ir@vbivaccines.com

         Investor Contacts

         Robert B. Prag, President
         The Del Mar Consulting Group, Inc.
         Phone: (858) 361-1786
         Email: bprag@delmarconsulting.com

         Scott Wilfong, President
         Alex Partners, LLC
         Phone: (425) 242-0891
         Email: scott@alexpartnersllc.com

(RVNC) to Initiate Two Key Trials for RT001 in Topical Botulinum Toxin

A Phase 3 Study for the Treatment of Lateral Canthal (Crow’s Feet) Lines and a Phase 2 Study for Treatment of Hyperhidrosis (Excessive Sweating) Are Expected to Begin Enrollment in the Second Half of 2015

NEWARK, Calif., June 3, 2015  — Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced its plans to move forward with two key clinical studies for its investigational drug product candidate RT001, a topical gel formulation of botulinum toxin type A.

“We recently conducted an open-label study for the treatment of crow’s feet lines, which enrolled an aggregate of 69 subjects across multiple sites. In the study, we evaluated the 28-day efficacy of a single topical application of the RT001 drug products tested. The subject response observed in the open-label study, taken together with our analysis of prior studies and early data from newly developed clinical methods, has led us to proceed with our RT001 U.S. Phase 3 clinical trial for the treatment of crow’s feet lines. Based upon what we have learned, we believe we have an opportunity to achieve clinical and statistical significance in a Phase 3 clinical study,” said Dan Browne, President and Chief Executive Officer at Revance. “We are making promising advances in the development of clinical methods, such as electromyography (EMG), intended to demonstrate the ability of RT001 to effectively cross the skin and achieve an associated paralytic effect directly on the target muscle,” continued Browne.

In the second half of 2015, Revance plans to initiate a U.S. Phase 3 pivotal study to evaluate the safety and efficacy of a single topical application of RT001 on adults with moderate to severe crow’s feet lines. The company also plans to begin a U.S. Phase 2 study to evaluate the safety and efficacy of a single application of topical RT001 on adults with moderate to severe axillary hyperhidrosis, or excessive sweating. Revance plans to provide trial design details and timelines for these studies when each commences later this year.

“We are pleased to be moving ahead with the development of RT001, which has the potential to transform today’s botulinum toxin market. By eliminating the need for needles in aesthetic and therapeutic treatments, we believe our topical RT001 could significantly expand the estimated $3 billion neurotoxin market by removing many of the barriers that currently keep patients from adopting its use, including pain and bruising,” concluded Browne.

RT001 and RT002 Drug Product Candidates

Revance is currently developing two botulinum toxin type A investigational drug product candidates. RT001 is a topical formulation, which has the potential to be the first commercially available non-injectable dose form of botulinum toxin type A. Revance is studying topical RT001 for aesthetic indications, such as crow’s feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). RT002 is a novel, injectable formulation of botulinum toxin type A designed to be more targeted and longer lasting than currently available injectable botulinum toxin products. Revance is studying injectable RT002 for aesthetic indications, such as glabellar (frown) lines and therapeutic uses, such as muscle movement disorders (cervical dystonia and upper limb spasticity). Both products would have the potential to expand into additional aesthetic and therapeutic indications in the future.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance’s proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for drug product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com.

“Revance Therapeutics”, TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about our RT001 investigational drug product candidate, including but not limited to statements regarding the process and timing of, and ability to complete, current clinical studies and anticipated future clinical development, the initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, goals and market for our anticipated products, plans and prospects; statements about our ability to obtain regulatory approval; statements about potential benefits of our drug product candidates and our technologies; and statements about future financial performance.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance’s periodic filings with the Securities and Exchange Commission (the “SEC”), including factors described in the section entitled described in the “Risk Factors” section of our quarterly report on Form 10-Q filed May 14, 2015. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

CONTACT: Investors:
         Revance Therapeutics
         Jeanie Herbert
         (714) 325-3584
         jherbert@revance.com

         Westwicke Partners
         Leigh Salvo
         (415) 513-1281
         leigh.salvo@westwicke.com

         Trade Media:
         Nadine Tosk
         (847) 920-9858
         nadinepr@gmail.com

(BLFS) Reports Increased Adoption of CryoStor® and HypoThermosol®

Embedded IP Helps Cellular Immunotherapy and Regenerative Medicine Customers Overcome Manufacturing & Commercialization Challenges

BOTHELL, Wash., June 3, 2015  — BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers (“BioLife” or the “Company”), today reported several new customer disclosures on the use of the Company’s CryoStor and HypoThermosol biopreservation media products in pre-clinical validation projects and clinical trials at the recent International Society for Cellular Therapy (ISCT) conference. Several posters citing the use of BioLife products included:

• GSK – poster: Overcoming automation and formulation challenges in the manufacture and distribution of next generation ex vivo gene therapy products.
  • Gene therapy: GSK2696273 – autologous CD34+ cells
  • Clinical indication: SCID due to adenosine deaminase deficiency
  • BioLife products used: CryoStor and HypoThermosol
  • Results: HypoThermosol enabled stability for 7 days and function for 3 days; At days 14, 21, and 28 DMSO and CryoStor were able to maintain CD34 expression

• HemaCare Bioresearch Products & Services – poster: Cryopreserved Leukopaks (LP) Maintain Cell Viability & Functionality.
  • Source material: leukapheresis collections
  • BioLife product used: CryoStor CS10
  • Results: WBC, CD3, and CD14 counts between fresh and frozen/thawed LP were not significantly different; Viability of the cells was greater than 99% in all cases when gated on FSC/PI; Dendritic cell (DC) generation and purity was similar in all cases

• MaSTherCell (for their customer Imcyse) – poster: Technology Transfer and Process Development for an Autologous Cell Therapy Against Multiple Sclerosis.
  • Cell therapy: Sclerolym T cell therapy
  • Clinical indication: Multiple Sclerosis
  • BioLife products used: CryoStor CS5 and CryoStor CS10
  • Results: “Switch to CryoStor solutions dramatically improved survival of mature DC”; “Sclerolym process was scaled-up, developed, and qualified as to allow timely start in phase 1 clinical studies.”

• RoosterBio – poster: Cryopreserved hMSC maintain comparable in vitro functional activity compared to fresh hMSC
  • Cellular product: human mesenchymal stem cells
  • BioLife product used: CryoStor CS5
  • Results: Cryopreservation does not affect IDO Induction by IFN-y + TNF-α or Angiogenic Cytokine Secretion Profile

At the ISCT conference, BioLife also presented and demonstrated the evo smart, precision thermal shipper and it’s connected, cloud hosted biologistex application which enables customers to pack, ship, and track high-value biologic based payloads including starting material for cell and tissue based products and manufactured cellular and regenerative medicine products and therapies.

A play on the word biologistics (defined as the processes, tools, and data used to monitor and manage the movement of biologic materials such as vaccines, cells, tissues, and organs across time and space), biologistex is poised to disrupt the 50 year old service chain for delivery logistics of biologic based materials through innovative, smart, precision thermal shipping containers and a cloud hosted logistics management application.

Mike Rice, BioLife Solutions President & CEO, remarked on the 2015 ISCT conference by stating, “This ISCT conference was a tremendous success for BioLife by any measure.  We learned of several new groups using our biopreservation media products in clinical applications.  Traffic at our exhibit was constant throughout the conference, as interest in our new evo smart shipper and cloud hosted biologistex app was very strong.  We captured dozens of qualified leads and this event reconfirmed our belief that we have a phenomenal opportunity to help our customer further optimize yield and cost in the manufacturing and delivery logistics of their biologic based therapies, while improving the quality of their distribution practices.”

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cloud-hosted logistics management applications for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company’s proprietary HypoThermosol^® and CryoStor^® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife’s enabling technologies provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning new products, the company’s anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, and, projected financial results and liquidity. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM’s products; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

(ARDX) to Raise $77.8 Million in a Private Placement, New Hyperkalemia Product

Ardelyx to Pursue an Accelerated 505b(2) Regulatory Pathway for RDX022 with Initiation of Phase 3 Program to Begin as Early as Second Half 2016 Conference Call and Webcast Today at 8:30am ET

FREMONT, Calif., June 3, 2015  — Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into an agreement to sell shares of its common stock and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $77.8 million in a private placement. New Enterprise Associates (NEA), the Company’s largest shareholder and one of the largest biotechnology investors worldwide, has committed to invest approximately $50.2 million in the private placement and a combination of new and existing investors, including RA Capital Management, Broadfin Capital LLC, Cormorant Asset Management LLC, Foresite Capital Management, LLC, Rock Springs Capital Management LP, and a fund managed by Sabby Capital, LLC, have committed to invest the remaining $27.6 million.  Additionally, Ardelyx announced a new program, RDX022, a non-absorbed polymer, for the treatment of hyperkalemia.

“Ardelyx’s clinical programs hold great promise, and we are excited to continue to play an important role in the Company’s growth,” said David Mott, Head of the Healthcare Practice at NEA and Chairman of Ardelyx. “Since our initial investment in 2008, Ardelyx is transforming into an emerging biotech company with a pipeline of proprietary and novel drug candidates that have a clear path to commercialization. The Company has an exceptional team that can advance its clinical programs and execute on its business strategy,” Mr. Mott added.

“Given the extensive expertise of the Ardelyx team in developing and commercializing minimally-absorbed products including polymers in the cardio-renal field, we are uniquely positioned to develop an improved potassium binder to manage hyperkalemia in chronic kidney and heart disease patients,” noted Mike Raab, President and CEO of Ardelyx. “Together with tenapanor and RDX013, our small molecule hyperkalemia program, RDX022 is an exciting program that augments a formidable pipeline of innovative products. This is a pivotal point in the history of Ardelyx and an exciting time for our company as we focus our efforts towards building a commercially-driven, fully-integrated company with wholly-owned products to transform the treatment paradigm in the indications that they treat.”

In a separate press release, the Company announced today it has regained from AstraZeneca the worldwide development and commercialization rights for its late-stage development candidate, tenapanor, and its related portfolio of NHE3 compounds. Proceeds from the private placement will be used to develop tenapanor and RDX022, two wholly-owned programs that have the potential to be in Phase 3 clinical trials in the fourth quarter of 2015 and second half of 2016, respectively.

About the Private Placement

Ardelyx will sell approximately 7.24 million shares of the common stock and warrants to purchase approximately 2.17 million shares of common stock for aggregate gross proceeds of approximately $77.8 million in the private placement. The price to be paid for the common stock, $10.70 per share, is equal to the consolidated closing bid price on the Nasdaq Global Market on the day of pricing, June 2, 2015. The warrants are exercisable at a price of $13.91 per share. The Company expects the offering to close by June 5, 2015 subject to satisfaction of specified customary closing conditions. Leerink Partners LLC is acting as the sole placement agent of the offering and Wedbush PacGrow acted as a financial advisor to Ardelyx in connection with this offering.

The securities to be sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and will be sold in a private placement pursuant to Regulation D of the Securities Act. The securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. Ardelyx has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors and shares of common stock issuable upon exercise of the warrants acquired by the investors.

About RDX022

RDX022 is a novel, non-absorbed polystyrene sulfonate polymer being developed by Ardelyx to treat elevated potassium, or hyperkalemia, a potentially dangerous problem common among patients with chronic kidney disease (CKD) and heart failure. RDX022 is designed with improved chemical and physical properties as well as formulation improvements that may allow for a more palatable dosage form.

The Company will be pursuing a 505b(2) regulatory pathway in the United States for RDX022, allowing Ardelyx a faster path to approval by referencing the literature and the U.S. Food and Drug Administration’s previous findings of safety and effectiveness of the referenced drug product.  Ardelyx will supplement this approach with nonclinical and Phase 3 clinical data on RDX022 to provide information for inclusion in the product label. The Company plans to progress RDX022 into late stage clinical development over the next 12-18 months.

Ardelyx will begin early stage clinical trials in mid-2015.  Assuming the successful completion of those trials, the Company expects to commence a Phase 3 clinical program to evaluate RDX022 for treatment in hyperkalemia patients as early as the second half of 2016.

Ardelyx is also continuing research on its RDX013 small molecule drug candidate for hyperkalemia.  This agent, a potential potassium secretagogue, is intended to enhance potassium secretion or prevent potassium absorption with a much lower pill burden than potassium binders and may provide significant advantages as a stand-alone agent or used in combination with the potassium binders, including RDX022.

Additional details on RDX022 and Ardelyx’s research and development programs will be presented at Ardelyx’s upcoming R&D Investor Day, planned for July 14th, 2015, in New York, NY.

About Hyperkalemia

Hyperkalemia is defined as the presence of blood potassium levels greater than 5.0mEq/L.  Normal levels are 3.5 to 5.0 mEq/L.  When hyperkalemia is severe, or above 7.0mEq/L, there is a significantly increased risk of death because of the potential for heart conductance problems.

Hyperkalemia can be caused by a variety of sources.  Kidney disease can result in the build-up of potassium in the blood.  Also, certain drugs such as the common blood pressure medications known as RAAS inhibitors, or inhibitors of the renin-angiotensin-aldosterone system, can cause hyperkalemia.  RAAS inhibitors, though quite effective for controlling blood pressure, are often significantly reduced in patients, such as in those with CKD and congestive heart failure, or CHF, whose potassium levels are elevated because of the fear that elevated potassium can cause significantly worse problems than hypertension including sudden cardiac arrest in severe cases.

According to Einhorn et al, about 21% and 42% of patients with CKD Stage 3b and Stage 4 had a hyperkalemic event during a 12-month period suggesting that acute hyperkalemia affects about 900,000 individuals with CKD stage 3b or 4 in the United States. There are approximately 1.9 million patients with stage 3b or 4 CKD who are taking RAAS inhibitors and about 10% of these patients, or about 190,000 patients, tend to have chronic problems with hyperkalemia. There are about 1.7 million stage 3b or 4 CKD patients who are not prescribed RAAS inhibitors.  Given that hypertension is present in a majority of these patients, the Company believes that many of these patients are not prescribed RAAS inhibitors because of the risk of hyperkalemia.  Recent data (Fraser 2013) suggests that of the 88% of CKD stage 3 patients with hypertension, only 36% achieved the target of 130/80 with over 35% not taking any RAAS inhibitors despite their known success in achieving blood pressure control. This supports the concept that a million or more CKD patients may be prescribed suboptimal doses of RAAS inhibitors with at least one reason being the avoidance of hyperkalemia.

Additionally, of the 5.7 million patients with heart failure, over half are prescribed RAAS inhibitors.  Again, these patients tend to receive suboptimal doses of RAAS inhibitors suggesting a large opportunity in this market as well.

Conference Call & Webcast Information

Ardelyx will host a live conference call and webcast today at 8:30am Eastern Time. The live webcast and a replay may be accessed by visiting Ardelyx’s website on the investor page of the Company’s website at http://ir.ardelyx.com/

Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen to the live conference call. The conference ID number for the live call is 59352386. Please dial in approximately 10 minutes prior to the call. An archived webcast replay will be available on the Company’s website for two weeks.

About Ardelyx

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, the Company has discovered and designed tenapanor. In addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients, and has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in CKD-5D, a program licensed to Sanofi.  Ardelyx is also independently advancing several research programs focused in cardio-renal, gastrointestinal and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx’s website at www.ardelyx.com.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for RDX022 in treating hyperkalemia, Ardelyx’s future development plans for RDX022 and the timing thereof, and the potential of Ardelyx’s drug discovery and design platform. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of tenapanor, or Ardelyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx’s quarterly report filed on Form 10-Q with the Securities and Exchange Commission on May 12, 2015, and its future periodic reports to be filed with the Securities and Exchange Commission.

(AMRS) Former Cargill Business Leader Bram Klaeijsen Appointed To Board of Directors

EMERYVILLE, Calif., June 2, 2015  — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the planned resignation of Dr. Nam-Hai Chua and the designation of Bram Klaeijsen to serve as a member of Amyris’s board of directors. Klaeijsen is a seasoned business leader from Cargill, Inc. (“Cargill”) and has served in various roles with affiliates of Temasek Holdings (“Temasek”). Klaeijsen is expected to replace Dr. Chua on the board of directors, pursuant to Temasek’s right to designate a director under an agreement among Temasek, Amyris and certain other investors on February 23, 2012.

“We are excited to welcome Bram as a designee to our Board of Directors and appreciate Temasek’s continued commitment to Amyris by designating him,” said John Melo, President & CEO of Amyris. “He has extensive global business leadership experience across a variety of key roles worldwide in the food and ingredients sectors and, in particular, as the President and Regional Director at Cargill Asia-Pacific. His deep experience will support our expanding role in several key global growth markets – including the Asia-Pacific region − where we are expanding with multiple growth opportunities as a leading provider of renewable products to the world’s leading brands.”

Continued Melo, “We’d also like to thank Dr. Chua for his service to Amyris since his appointment in 2012 to our board and the role he has played in helping to guide the company in its continued development and growth as a leader in its space. We wish him well in his pursuit of other professional commitments.”

Klaeijsen is currently engaged as a corporate advisor with Temasek and has served on the boards of directors of several companies, including Cargill Tropical Palm Holdings Pte Ltd., a joint venture between Temasek and Cargill from 2010 through January 2015. Previously, he served as President and Regional Director, Asia-Pacific, and Platform Leader for Cargill Food Ingredients and Systems, a division of Cargill, from which he retired in January 2015. Klaeijsen joined Cargill in 1978 and held a number of leadership positions, including as Platform Leader for Cargill’s European Food Ingredients businesses from 1999 to 2003, when he assumed the role of Executive Vice President of Cargill Food Ingredients and Systems. He held that position until he joined Cargill’s Asia-Pacific operations in 2009, where he served until his retirement. Klaeijsen holds a Bachelor of Science degree in chemical engineering from technical college Breda in the Netherlands.

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as expectations regarding board of director composition and the ability of Amyris to leverage its role as a provider of renewable products in order to achieve growth) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including, among other things, that Mr. Klaeijsen is ultimately not appointed to serve on the Board, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-Q filed on May 5, 2015. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris is a registered trademark of Amyris, Inc.

CONTACT: Peter DeNardo
         Director, Investor Relations and Corporate Communications
         Amyris, Inc.
         +1 (510) 740-7481
         investor@amyris.com

(INVE) & Other Security Thought Leaders Featured on SecuritySolutionsWatch.com

(LPTH) Announces Update on New Infrared Product Line

(IKGH) Rolling Chip Turnover of US$0.68 Billion for May 2015

Iao Kun Group Holding Company Limited (“IKGH”) (NASDAQ:IKGH), which operates through its subsidiaries and related promotion entities that act as VIP room gaming promoters and a collaborator, today announced unaudited Rolling Chip Turnover (as defined below) for the month of May 2015 at the company’s VIP rooms in Macau was US$0.68 billion, down 57% year-over-year, compared to US$1.59 billion for the month of May 2014. Win rate for the month of May 2015 was 1.86%.

For the first five months of 2015, IKGH’s Rolling Chip Turnover was US$3.38 billion (an average of $0.68 billion per month), down 58% year-over-year, compared to US$8.08 billion (an average of $1.62 billion per month) for the first five months of 2014.

The Company’s VIP rooms are primarily focused on high stakes baccarat. Baccarat accounts for approximately 88% of total Macau casino winnings according to the Macau Gaming Inspection and Coordination Bureau (DICJ). In Macau, two remuneration methods are used to compensate VIP room gaming promoters. On a fixed commission basis, VIP room gaming promoter revenues are based on an agreed percentage of Rolling Chip Turnover. On a win/loss split basis, the VIP room gaming promoter receives an agreed percentage of the “win” in the VIP gaming room (plus certain incentive allowances), and is required to also bear the same percentage of losses that might be incurred. Compared to the fixed commission basis, the win/loss split basis subjects the VIP room gaming promoter to the risk of losses from the gaming patron’s activity and to greater volatility.

As of September 1, 2012, all IKGH VIP rooms are on a revenue sharing remuneration model.

Definition of Rolling Chip Turnover

Rolling Chip Turnover is used by casinos to measure the volume of VIP business transacted and represents the aggregate amount of non-negotiable chips players purchased. Bets are wagered with “non-negotiable chips” and winning bets are paid out by casinos in so-called “cash” chips. “Non-negotiable chips” are specifically designed for VIP players to allow casinos to calculate the commission payable to VIP room gaming promoters. Commissions are paid based on the total amount of “non-negotiable chips” purchased by each player. VIP room gaming promoters therefore require the players to “roll,” from time to time, their “cash chips” into “non-negotiable” chips for further betting (hence the term “Rolling Chip Turnover”). Through the promoters, “non-negotiable chips” can be converted back into cash at any time. Betting using rolling chips, as opposed to using cash chips, is also used by the DICJ to distinguish between VIP table revenue and mass market table revenue.

All IKGH VIP rooms are on a revenue sharing remuneration model. On a win/loss split basis, the VIP room gaming promoter receives an agreed percentage of the “win” in the VIP gaming room (plus certain incentive allowances), and is required to also bear the same percentage of losses that might be incurred.

About Iao Kun Group Holding Company Limited

IKGH is a holding company which operates through its subsidiaries and related promotion entities that act as VIP room gaming promoters and a collaborator, and is entitled to receive all of the profits of the VIP gaming promoters and collaborator from VIP gaming rooms. IKGH’s VIP room gaming promoters and collaborator currently participate in the promotion of five major luxury VIP gaming facilities in Macau, China, the largest gaming market in the world. One VIP gaming room is located at the top-tier 5-star hotel, the StarWorld Hotel & Casino in downtown Macau, and another is located in the luxury 5-star hotel, the Galaxy Macau™ Resort in Cotai, each of which is operated by Galaxy Casino, S.A. Additional VIP gaming rooms are located at the Sands Cotai Central and City of Dreams Macau, both in Cotai, and Le Royal Arc Casino, located in NAPE, Downtown Macau.

(WILN) Acquires Qimonda Patent Portfolio from Infineon

For media and investor inquiries
Tyler Burns
Director, Investor Relations
O: 613.688.4330
C: 613.697.0367
tburns@wilan.com